Page 39 - Read Online

Brooks et al. Rare Dis Orphan Drugs J 2024;3:15 https://dx.doi.org/10.20517/rdodj.2023.27 Page 13 of 14
NIH support rare disease research portfolios. One example is the recently developed Ultra-rare Gene-based
Therapy (URGenT) Network, supported by the National Institute of Neurological Disorders and Stroke
(NINDS). Indeed, as we noted above, nearly all DRDRI programs and activities listed here are collaborative
efforts that involve working with other divisions of NCATS, other NIH Institutes and Centers, and external
partners both within the U.S. and internationally. We believe that such a collaborative approach is essential
to effectively advancing and navigating a global rare disease community.

DECLARATIONS
Authors’ contributions
Made final edits: Brooks PJ
Prepared the bibliography: Lumsden J
Writing of the manuscript: Brooks PJ, Grady AC, Groft S, Ho L, Lumsden J, Shah M, Sid E, Xu Y, Tisdale A,
Dickens J, Pichard D, Urv T

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate.
Not applicable.

Consent for publication.
Not applicable.

Copyright
© The Author(s) 2024.

REFERENCES
1. RARE-X. The power of being counted. 2022. Available from: https://rare-x.org/case-studies/the-power-of-being-counted/ [Last
accessed on 3 Jun 2024].
2. Haendel M, Vasilevsky N, Unni D, et al. How many rare diseases are there? Nat Rev Drug Discov 2020;19:77-8. DOI PubMed PMC
3. Garrison S, Kennedy A, Manetto N, Pariser AR, Rutter JL, Yang G. The economic burden of rare diseases: quantifying the sizeable
collective burden and offering solutions. Health Affairs Forefront. 2022. DOI
4. Tisdale A, Cutillo CM, Nathan R, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare
systems. Orphanet J Rare Dis 2021;16:429. DOI PubMed PMC
5. Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now? The impact of health-care utilization by
rare disease patients in the United States. Genet Med 2021;23:2194-201. DOI PubMed PMC
6. Kariampuzha WZ, Alyea G, Qu S, et al. Precision information extraction for rare disease epidemiology at scale. J Transl Med
2023;21:157. DOI
7. Zhu Q, Qu C, Liu R, et al. Rare disease-based scientific annotation knowledge graph. Front Artif Intell 2022;5:932665. DOI PubMed
PMC
8. Lumsden JM, Urv TK. The rare diseases clinical research network: a model for clinical trial readiness. Ther Adv Rare Dis
2023;4:26330040231219272. DOI PubMed PMC
9. Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with
implications for diabetes. Nat Genet 2020;52:473-81. DOI
10. Applied Therapeutics. Applied therapeutics announces initiation of registrational phase 2/3 study of AT-007 in SORD deficiency.
2021. Available from: https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-initiation-
registrational-phase [Last accessed on 3 Jun 2024].